» Articles » PMID: 32304772

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

Abstract

Background: The novel coronavirus disease 2019 (COVID-19) has become a global health emergency. The cumulative number of new confirmed cases and deaths are still increasing out of China. Independent predicted factors associated with fatal outcomes remain uncertain.

Research Question: The goal of the current study was to investigate the potential risk factors associated with fatal outcomes from COVID-19 through a multivariate Cox regression analysis and a nomogram model.

Study Design And Methods: A retrospective cohort of 1,590 hospitalized patients with COVID-19 throughout China was established. The prognostic effects of variables, including clinical features and laboratory findings, were analyzed by using Kaplan-Meier methods and a Cox proportional hazards model. A prognostic nomogram was formulated to predict the survival of patients with COVID-19.

Results: In this nationwide cohort, nonsurvivors included a higher incidence of elderly people and subjects with coexisting chronic illness, dyspnea, and laboratory abnormalities on admission compared with survivors. Multivariate Cox regression analysis showed that age ≥ 75 years (hazard ratio [HR], 7.86; 95% CI, 2.44-25.35), age between 65 and 74 years (HR, 3.43; 95% CI, 1.24-9.5), coronary heart disease (HR, 4.28; 95% CI, 1.14-16.13), cerebrovascular disease (HR, 3.1; 95% CI, 1.07-8.94), dyspnea (HR, 3.96; 95% CI, 1.42-11), procalcitonin level > 0.5 ng/mL (HR, 8.72; 95% CI, 3.42-22.28), and aspartate aminotransferase level > 40 U/L (HR, 2.2; 95% CI, 1.1-6.73) were independent risk factors associated with fatal outcome. A nomogram was established based on the results of multivariate analysis. The internal bootstrap resampling approach suggested the nomogram has sufficient discriminatory power with a C-index of 0.91 (95% CI, 0.85-0.97). The calibration plots also showed good consistency between the prediction and the observation.

Interpretation: The proposed nomogram accurately predicted clinical outcomes of patients with COVID-19 based on individual characteristics. Earlier identification, more intensive surveillance, and appropriate therapy should be considered in patients at high risk.

Citing Articles

Clinico-demographic factors affecting mortality in COVID-19 patients at a health care facility, Western Uttar Pradesh.

Singh S, Sisodia A, Athwani M J Family Med Prim Care. 2025; 14(1):196-200.

PMID: 39989592 PMC: 11844968. DOI: 10.4103/jfmpc.jfmpc_983_24.


Advantages of Metabolomics-Based Multivariate Machine Learning to Predict Disease Severity: Example of COVID.

Lepoittevin M, Remaury Q, Leveque N, Thille A, Brunet T, Salaun K Int J Mol Sci. 2024; 25(22).

PMID: 39596265 PMC: 11594300. DOI: 10.3390/ijms252212199.


Fragmentomics of plasma mitochondrial and nuclear DNA inform prognosis in COVID-19 patients with critical symptoms.

Zhang H, Li L, Luo Y, Zheng F, Zhang Y, Xie R BMC Med Genomics. 2024; 17(1):243.

PMID: 39363185 PMC: 11451003. DOI: 10.1186/s12920-024-02022-2.


Survival of hospitalised COVID-19 patients in Hawassa, Ethiopia: a cohort study.

Anteneh A, LeBlanc M, Natnael A, Asfaw Z BMC Infect Dis. 2024; 24(1):1055.

PMID: 39333929 PMC: 11429985. DOI: 10.1186/s12879-024-09905-w.


Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.

De Rop L, Bos D, Stegeman I, Holtman G, Ochodo E, Spijker R Cochrane Database Syst Rev. 2024; 8():CD015050.

PMID: 39105481 PMC: 11301994. DOI: 10.1002/14651858.CD015050.pub2.


References
1.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

2.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

3.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

4.
Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck E . Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019; 57(9):1308-1318. DOI: 10.1515/cclm-2018-1181. View

5.
de Jong E, van Oers J, Beishuizen A, Vos P, Vermeijden W, Haas L . Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016; 16(7):819-827. DOI: 10.1016/S1473-3099(16)00053-0. View